Effect of orlistat combined intervention on androgen and glycolipid metabolism in overweight or obese polycystic ovary syndrome patients

doi:10.3969/j.issn.1006-7795.2019.04.015

Abstract

Abstract: Objective To investigate the effect of orlistat combined intervention on anthropometry,androgen,glucose and lipid metabolism in overweight or obese patients with polycystic ovary syndrome (PCOS). Methods Totally 75 overweight or obese PCOS patients[body mass index(BMI) ≥ 24kg/m²]were admitted to the Department of Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,from May to September 2018,numbered according to the order of treatment and randomly divided into two groups.Group 1 included 50 patients,orlistat plus drospirenone and ethinylestradiol tablets(Ⅱ) (Yaz) comprehensive intervention;Group 2 included 25 patients treated with Yaz alone.The changes of anthropometry,androgen,glucose and lipid metabolism,liver and kidney function indexes before and after 3 months of treatment in the two groups were compared. Results After 3 months of treatment,the body weight,waist circumference,hip circumference and BMI of orlistat plus Yaz comprehensive intervention group and Yaz alone group were significantly decreased,but the decrease of orlistat plus Yaz comprehensive intervention group was significantly greater than those Yaz alone group(P<0.05).Among the hormone indicators, free testosterone (FT),sex hormone-binding globulin(SHBG) of the two groups were significantly changed, but there was no statistically significant difference in the degree of change between the two groups (P>0.05).Glucose and lipid metabolism,liver and kidney function were all changed, and there was no statistically significant difference between the two groups (P>0.05). Conclusion Orlistat combined with Yaz was superior to Yaz alone in decreasing the body weight and waist circumference of overweight or obese PCOS patients,providing a basis for clinical rational drug selection.

Key words: overweight or obese, polycystic ovary syndrome, orlistat, drospirenone and ethinylestradiol tablets(Ⅱ) (Yaz)

CLC Number:

R711.75

Min Min, Ruan Xiangyan, Zhao Yue, Wang Husheng, Cheng Jiaojiao, Luo Suiyu, Xu Zhongting, Li Meng, Zhang Luping, Wang Yuejiao, Alfred O. Mueck. Effect of orlistat combined intervention on androgen and glycolipid metabolism in overweight or obese polycystic ovary syndrome patients[J]. Journal of Capital Medical University, 2019, 40(4): 572-577.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.04.015

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I4/572

References 27

[1]	Alves E D, Bonfá A L O, Pigatto G R, et al. Photobiomodulation can improve ovarian activity in polycystic ovary syndrome-induced rats[J]. J Photochem Photobiol B, 2019, 194:6-13.
[2]	Bhatnager R, Jalthuria J, Sehrawat R, et al. Evaluating the association of TNF α promoter haplotype with its serum levels and the risk of PCOS:A case control study[J]. Cytokine, 2019,114:86-91.
[3]	Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS[J]. PLoS One, 2017,12(11):e0186136-e0186136.
[4]	Dumesic D A, Oberfield S E, Stener-Victorin E,et al. Scientific statement on the diagnostic criteria,epidemiology,pathophysiology,and molecular genetics of polycystic ovary syndrome[J].Endocr Rev,2015,36(5):487-525.
[5]	Dahan M H, Reaven G. Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome[J]. Endocrine, 2019, 64(3):685-689.
[6]	Glueck C J, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome:etiology, treatment, and genetics[J]. Metabolism, 2019, 92:108-120.
[7]	Celik O, Aydin S, Celik N,et al. Molecular role of peptides/proteins in subfertility of polycystic ovarian syndrome[J]. Cell Mol Biol(Noisy-le-Grand), 2019, 65(3):32-40.
[8]	Ruan X Y, Li M, Mueck A O. Why does polycystic ovary syndrome (PCOS) need long-term management?[J].Curr Pharm Des, 2018,24(39):4685-4692.
[9]	Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder:significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)[J]. Life Sci, 2019,228:167-175.
[10]	中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合症中国诊疗指南[J].中华妇产科杂志, 2018,53(1):2-6.
[11]	Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J].Hum Reprod,2004,19(1):41-47.
[12]	中国肥胖问题工作组. 中国成人超重和肥胖症预防与控制指南[J].营养学报, 2004,26(1):1-4.
[13]	Naderpoor N, Shorakae S, Joham A, et al. Obesity and polycystic ovary syndrome[J]. Minerva Endocrinol, 2015,40(1):37-51.
[14]	金婧, 阮祥燕,华琳,等.多囊卵巢综合征卵巢储备功能降低患者肥胖及糖脂代谢特征[J].首都医科大学学报,2018,39(4):505-511.
[15]	Kumar P,Arora S.Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates[J].J Hum Repord Sci, 2014,7(4):255-261.
[16]	张国毅,林彤. 口服屈螺酮炔雌醇片治疗女性中度寻常痤疮的多中心、随机、安慰剂对照临床研究[J]. 中华皮肤科杂志,2015, 48(2):85-88.
[17]	Panda S R, Jain M, Jain S, et al. Effect of orlistat versus metformin in various aspects of polycystic ovarian syndrome:a systematic review of randomized control trials[J]. J Obstet Gynaecol India, 2018,68(5):336-343.
[18]	Patni N, Quittner C, Garg A. Orlistat therapy for children with type 1 hyperlipoproteinemia:a randomized clinical trial[J]. J Clin Endocrinol Metab, 2018,103(6):2403-2407.
[19]	Saleh A, ElFayoumi H M,Youns M, et al. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions[J]. Naunyn Schmiedeberg's Arch Pharmacol, 2019,392(2):165-175.
[20]	Moini A,Kanani M,Kashani L,et al.Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome:a randomized double-blind placebo-controlled trial[J].Edocrine,2015,49(1):286-289.
[21]	Gallo M F, Lopez L M, Grimes D A, et al. Combination contraceptives:effects on weight[J]. Cochrane Database Syst Rev,2014,29(1):CD003987.
[22]	Choi J, Kim K J, Koh E J, et al. Gelidium elegans regulates the AMPK-PRDM16-UCP-1 pathway and has a synergistic effect with orlistat on obesity-associated features in mice fed a high-fat diet[J]. Nutrients, 2017,9(4):pii:E342.
[23]	Keevil B G, Adaway J. Assessment of free testosterone concentration[J]. J Steroid Biochem Mol Biol, 2019, 190:207-211.
[24]	Song J, Ruan X, Gu M, et al. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance[J]. Gynecol Endocrinol,2018,34(5):413-417.
[25]	Ghandi S, Aflatoonian A, Tabibnejad N, et al. The effects of metformin or orlistat on obese women with polycystic ovary syndrome:a prospective randomized open-label study[J]. J Assist Reprod Genet,2011,28(7):591-596.
[26]	Alqahtani S, Qosa H, Primeaux B, et al. Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1(NPC1L1) inhibition[J]. Eur J Pharmacol,2015,762(3):263-269.
[27]	de Bastos M, Stegeman B H, Rosendaal F R, et al. Combined oral contraceptives:venous thrombosis[J]. Cochrane Database Syst Rev,2014,3:CD010813.